No Data
Hao Oubo (688656.SH): The actual controller has changed to SINO BIOPHARM.
On December 13, Gala Globe announced that Hao Ou Bo (688656.SH) reported that, according to the "Transfer Registration Confirmation" issued by the China Securities Depository and Clearing Co., Ltd. on December 13, 2024, the registration procedures for this share transfer have been completed. The transfer date is December 12, 2024, with a transfer of 18,670,878 shares, accounting for 29.99% of the total shares of Hao Ou Bo after excluding the shares in the repurchase special account. The nature of the shares is unlimited circulating shares. After the completion of this share transfer and the waiver of voting rights, Hui Huang Run Kang holds 18,670,878 shares in the company.
BOCOM INTL: Assigns a "Leading" rating to the domestic Pharmaceutical Industry. Shanghai establishes a 10 billion yuan M&A Fund, which is beneficial for accelerating industry consolidation.
BOCOM INTL believes that the pharmaceutical Sector still has further room for recovery.
Hong Kong Stock Announcement Gold Mining | Kanzhun's net profit in the third quarter reached a quarterly historical high with a year-on-year increase of 30% in active users.
Peking Autos (01958): Beiqi Investment and Hyundai Motor jointly invested approximately 1.095 billion US dollars in Beijing Hyundai.
Sino Biopharmaceutical Gets China Nod to Market Breast Cancer Drug
SINO BIOPHARM (01177.HK): "Methanesulfonic acid ailibrutinib injection" has been approved for market.
Gelonghui reported on December 11 that SINO BIOPHARM (01177.HK) announced that the "Epirubicin Hydrochloride Injection" (trade name: Ailelin) developed by the group has received marketing approval from the National Medical Products Administration of China, for the treatment of patients with locally advanced or metastatic breast cancer who have previously received at least two chemotherapy regimens (including anthracyclines and taxanes). This is one of the first three Epirubicin Hydrochloride Injections approved for sale in China. Epirubicin is a synthetically derived sponge B structural analog and is a novel non-taxane microtubule protein inhibitor, due to its mechanism of action being different from traditional microtubule inhibitors like taxanes.
Express News | Sino Biopharmaceutical - Eribulin Mesilate Injection Obtained Approval for Marketing From Nmpa
No Data
